Radiographic Findings and other Predictors in Adults with Covid-19

Kaiyan Li¹, Dian Chen¹, Shenchong Chen¹, Yuchen Feng¹, Chenli Chang¹, Zi

Wang², Nan Wang², Guohua Zhen^{1,*}

¹Division of Respiratory and Critical Care Medicine, Department of Internal Medicine,

and ²Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong

University of Science and Technology, Wuhan, China

*Correspondence to: ghzhen@tjh.tjmu.edu.cn

As of March 20, 2020, there were 234,073 confirmed cases of coronavirus disease

2019 (Covid-19) and 9,840 deaths worldwide ¹. Older age and elevated d-dimer are

reported risk factors for Covid-19^{2,3}. However, whether early radiographic change is a

predictor of fatality remains unknown. We retrospectively reviewed records of all

laboratory-confirmed patients admitted to a quarantine unit at Tongji Hospital, a large

regional hospital in Wuhan, China, between January 31 and March 5, 2020. The Tongji

Hospital ethics committee approved this study.

A total of 128 patients were admitted. 102 patients were confirmed to have severe

acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection using RNA

detection. As of March 20, 82 confirmed patients were discharged, 15 died, and 5

remained hospitalized. The median age was 57 years (range, 27 - 85), 59 (58%) were

male, and 44 (43%) patients had a comorbidity. The most common symptoms were

fever, cough, and dyspnea (Table S1). When compared with survivors, non-survivors

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

We're proprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

(LDH), elevated d-dimer, and increased hypersensitive troponin I (Table S1, S2). In a multivariate regression model that included these predictors, older age and elevated LDH were independent risk factors for fatality (Table S3).




Figure 1. Total severity score and the number of involved lung lobes in CT images. A-B, total severity score (A) and the number of involved lung lobes (B) for CT images of survivors and non-survivors within the first week (\leq 7d) after symptom onset. C, total severity score for CT images of survivors over the 4 weeks after symptom onset. Values of survivors and non-survivors are presented with open and closed circles, respectively. Mann-Whitney U test was used to compare the values of survivors in Week 1 with those of non-survivors, and with those of survivors in Week 2, 3, 4, respectively. ****, p < 0.0001; **, p < 0.01; *, p < 0.05.

Twenty-one survivors and 11 non-survivors had CT scans within the first week. We used severity score to quantify the extent of lung opacification as described in the

Supplementary Appendix. The total severity score and number of involved lung lobes

within the first week were significantly greater in non-survivors compared to survivors

(Table S4). Using univariate logistic regression analysis, higher total severity score (≥15)

(odds ratio 53, 95% CI 3-369; p = 0.003), and more involved lung lobes (5 involved

lobes) (9, 2-53; p = 0.016) in CT images within the first week were significantly

associated with fatality (Figure 1A B, Table S5). Moreover, in this subset of patients

with CT data within the first week, higher total severity score was the only independent

risk factor in a multivariate analysis incorporated the predictors discussed above (older

age, lymphocytopenia, elevated LDH, elevated d-dimer, and increased troponin I)

(Table S5). For survivors with serial CT scans performed over four weeks, total severity

score peaked in the second week (Figure 1C, Table S4).

This report suggests that the extent of lung lesions in early CT images is a potential

predictor of poor outcome of Covid-19. This will help clinicians to identify the patients

with poor prognosis at early stage.

References:

1. World Health Organization. Coronavirus disease 2019 (COVID-19): situation report-

60 (https://www.who.int/docs/default-source/coronaviruse/situation-reports/

20200320-sitrep-60-covid-19.pdf?sfvrsn=d2bb4f1f 2)

2. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult

inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020

Mar 11. pii: S0140-6736(20)30566-3. doi: 10.1016/S0140-6736(20)30566-3. [Epub

3 / 27

ahead of print]

3. Wu C, Chen X, Cai Y, et al. Risk Factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Internal Medicine. 2020 Mar 13. doi: 10.1001/jamainternmed.2020.0994. [Epub ahead of print]

Supplementary Appendix

Radiographic Findings and other Predictors in Adults with Covid-19

Kaiyan Li, Dian Chen, Shengchong Chen, Yuchen Feng, Chenli Chang, Zi Wang, Nan

Wang, Guohua Zhen

Table of contents

Table S1. Demographics and baseline characteristics of patients with Covid-19......9 Table S3. Risk factors associated with fatality......14 Table S4. CT features of patients with Covid-19......16 Table S5. Risk factors associated with fatality of the subset of patients included in the Table S6. Demographics and baseline characteristics of the subset of patients included Table S7. Laboratory findings of the subset of patients included in the analysis of CTs performed within the first week after symptom onset......21 Figure S1. Transverse CT images of a 38-year-old man with COVID-19......24 Figure S2. Transverse CT images of a 41-year-old woman with Covid-19......25

Methods

Study Population and Data Collection

This retrospective study was approved by the institutional ethics board of Tongji Hospital of Huazhong University of Science and Technology. Written informed consent was waived. The study included all patients with laboratory-confirmed COVID-19 admitted to a quarantine unit of Tongji Hospital, a large regional hospital in Wuhan, China, between January 31 and March 5, 2020. COVID-19 patients were diagnosed according to World Health Organization (WHO) interim guideline ¹. Confirmed cases were defined by the positive findings in reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay of throat swab specimens. Clinical characteristics, laboratory test results, and treatment information were extracted from electronic medical records. All laboratory testing and radiological examination were performed according to the

RT-PCR for SARS-CoV-2

clinical care needs of the patient.

Throat swab specimens were tested for SARS-CoV-2 using real-time RT-PCR according to the WHO protocol ³. The following primers and probes were used for real-time RT-PCR detection of N gene of SARS-CoV-2: N forward primer 5'-GAGCCTTGAATACACCAAAAG-3', N reverse primer 5'-GCACGATTGCAGCATTGTTAGCAGGATT-3', N probe 5'-FAMCACATTGGCACCCGCAATCC-MGB-3'. Positive results were confirmed in two independent real-time RT-PCR assays.

Chest CT Protocols and Evaluation

High-resolution transverse CT images were obtained using Optima 660 (GE Medical

perpetuity.
All rights reserved. No reuse allowed without permission.

System, Milwaukee, USA) or Somatom Definition AS+ (Siemens Healthineers,

Forchheim, Germany). Tube voltage was 100 or 120 kV, and automatic tube current

modulation was 100 - 400 mA. All images were reconstructed with a slice thickness of

1.0mm or 1.25mm. The CT images were reviewed by two radiologists (ZW and NW)

who were blinded to the final outcome of the patients. Images were reviewed

independently. Any disagreements were resolved by discussion and consensus.

A scoring system was used to estimate the extent of lung opacification based on the

area involved ². Each of the five lung lobes was visually scored from 0 to 5 as: 0, no

involvement; 1, < 5% involvement; 2, 5% - 25% involvement; 3, 26% - 49%

involvement; 4, 50% - 75% involvement; 5, > 75% involvement. The total severity

score was the sum of scores of each lobe, ranging from 0 (no involvement) to 25

(maximum involvement).

Statistical Analysis

Statistical analysis was done with SPSS Statistics Software (version 26; IBM, New

York, USA). Continuous variables were presented as median (IQR) and analyzed using

Mann-Whitney U test; categorical variables were presented as number (%) and

analyzed by χ^2 test or Fisher's exact test between survivors and non-survivors where

appropriate. Univariable and multivariable logistic regression models were used to

estimate odds ratios and the 95% confidence intervals of the risk factors associated with

fatal outcome. A two-sided α of less than 0.05 was considered statistically significant.

Table S1. Demographics and baseline characteristics of patients with Covid-19

	Total	Non-survivor	Survivor	p value
	(n=102)	(n=15)	(n=87)	
Characteristics				
Age, years	57(45-70)	69(58-77)	55(44-66)	0.003
<65	70 (69%)	6 (40%)	64 (74%)	0.010
≥65	32 (31%)	9 (60%)	23 (26%)	
Sex				0.188
Female	43 (42%)	4 (27%)	39 (45%)	
Male	59 (58%)	11 (73%)	48 (55%)	
Any Comorbidity	44 (43%)	9 (60%)	35 (40%)	0.153
Diabetes	15 (15%)	2 (13%)	13 (15%)	0.871
Hypertension	31 (30%)	7 (47%)	24 (28%)	0.138
Coronary heart disease	4 (4%)	2 (13%)	2 (2%)	0.042
Chronic obstructive	2 (2%)	1 (7%)	1 (1%)	0.155
pulmonary disease				
Malignancy	5 (5%)	0 (0%)	5 (6%)	1.000
Chronic liver disease	3 (3%)	0 (0%)	3 (3%)	1.000
Other	28 (27%)	5 (33%)	23 (26%)	0.580
Current smoker	7 (7%)	1 (7%)	6 (7%)	0.974
Signs and symptoms				
Fever	94 (92%)	14 (93%)	80 (92%)	0.854
Highest temperature, °C	38.6(38.0-39.0)	38.5(38.0-38.9)	38.6(38.0-39.0)	0.458
Chills	23 (23%)	3 (20%)	20 (23%)	0.798
Cough	77 (75%)	13 (87%)	64 (74%)	0.276
Sputum	26 (25%)	6 (40%)	20 (23%)	0.163
Dyspnea	52 (51%)	7 (48%)	45 (52%)	0.717
Hemoptysis	5 (5%)	1 (7%)	4 (5%)	0.732
Chest pain	7 (7%)	1 (7%)	6 (7%)	0.974
Headache	18 (18%)	3 (20%)	15 (17%)	0.796
Fatigue	35 (34%)	5 (33%)	30 (34%)	0.931
Nausea	6 (6%)	1 (7%)	5 (6%)	0.889
Diarrhea	18 (18%)	4 (27%)	14 (16%)	0.321
Myalgia	24 (24%)	3 (20%)	21 (24%)	0.727
Systolic pressure, mm Hg	129.0(112.0-	144.0(126.0-	127.0(112.0-	0.009
	144.0)	170.0)	141.0)	
Heart rate, beats per minute	93.0(80.0-103.0)	102.0(86.0- 111.0)	92.0(80.0-103.0)	0.161
Respiratory rate	20.0(20.0-24.0)	24.0(21.0-25.0)	20.0(20.0-23.0)	0.003
>20 breaths per min	47 (46%)	12 (80%)	35 (40%)	0.004
Time from symptom onset	11.0(7.0-16.0)	9.0(6.0-14.0)	11.0(8.0-18.0)	0.291
to hospital admission, days	- ()	- ()	-()	

Data are median (IQR), n (%), or n/N (%), where N is the total number of patients with available data. p values comparing survivor with non-survivor were calculated by χ^2 test, Fisher's exact test, or Mann-Whitney U test, as appropriate. Covid-19, coronavirus disease 2019.

Table S2. Laboratory findings of patients with Covid-19 on admission

valu e 0.01 1 0.01 9
0.01 1 0.01
1 0.01
0.01
9
0.00
6
0.00
6
0.18
0
0.57
1
0.00
1
0.00
0
0.00
0
0.06
0
0.00
0
0.00
2
0.00
0.00
1
0.00
1
0.00
0.00

Hypersensitive troponin I,	≤34.2	5.2(2.2-	24.1(13.0-	4.3(2.0-	0.00
pg/mL		16.2)	202.1)	10.6)	0
≤34.2		88/101	8 (53%)	80/86	0.00
		(87%)		(93%)	0
>34.2		13/101	7 (47%)	6/86 (7%)	
		(13%)			
NT-proB-type Natriuretic	<241	131.0(53.5-	817.5(348.5-	92.5(42.3-	0.00
Peptide (BNP), pg/mL		355.8)	3031.0)	266.5)	0
<241		64/100	1/14 (7%)	63/86	0.00
		(64%)		(73%)	0
≥241		36/100	13/14 (93%)	23/86	
		(36%)		(27%)	
Albumin, g/L	35-52	34.8(31.7-	31.5(28.5-	36.5(32.5-	0.00
		39.5)	34.0)	39.8)	2
<35		52 (51%)	13 (97%)	39 (45%)	0.00
					3
≥35		50 (49%)	2 (13%)	48 (55%)	
Alanine aminotransferase,	≤41	23.0(14.0-	17.0(13.0-	23.0(14.0-	0.22
U/L		34.3)	29.0)	35.0)	3
≤41		86 (84%)	14 (93%)	72 (83%)	0.29
					8
>41		16 (16%)	1 (7%)	15 (17%)	
Aspartate aminotransferase,	≤40	26.0(19.0-	34.0(24.0-	25.0(19.0-	0.18
U/L		41.8)	54.0)	38.0)	7
≤40		75 (74%)	9 (80%)	66 (76%)	0.19
		27 (2(0))			8
>40	.26	27 (26%)	6 (20%)	21 (24%)	
Total bilirubin, μmol/L	≤26	8.5(6.6-	8.4(6.6-15.3)	8.5(6.6-	0.75
C 1/T	5 0.104	11.6)	040/600	11.4)	2
Creatinine, µmol/L	59-104	68.0(59.5-	94.0(63.0-	67.0(58.0-	0.01
-104		84.3)	164.0)	84.0)	4
≤104		89 (87%)	9 (60%)	80 (92%)	0.00
. 104		12 (120/)	(400/)	7 (00/)	1
>104	2 6 0 5	13 (13%)	6 (40%)	7 (8%)	0.00
Blood urea nitrogen, mmol/L	3.6-9.5	4.6(3.2-6.2)	9.2(5.4-13.7)	4.3(3.2-5.5)	0.00
~0.5		01 (000/)	0 (530/)	02 (0(0/)	0
≤9.5		91 (89%)	8 (53%)	83 (96%)	0.00
>0.5		11 (110/)	7 (470/)	4 (4%)	0
>9.5	2 50 5 10	11 (11%)	7 (47%)	* *	0.17
Potassium, mmol/L	3.50-5.10	4.2(3.8-4.5)	4.4(3.6-5.1)	4.1(3.8-4.5)	0.17
<3.5		12 (120/)	2 (120/)	11 (120/)	
<3.5		13 (13%)	2 (13%)	11 (13%)	0.01
3 5 5 1		81 (79%)	9 (60%)	72 (820/.)	۷
3.5-5.1		01 (7970)	9 (0070)	72 (83%)	

>5.1		8 (8%)	4 (27%)	4 (4%)	
Sodium, mmol/L	136-145	137.7(135.8	138.6(133.9-	137.6(136.	0.97
		-141.1)	142.6)	0-141.1)	0
<136		26 (25%)	5 (33%)	21 (24%)	0.24
					8
136-145		74 (73%)	9 (60%)	65 (75%)	
>145		2 (2%)	1 (7%)	1 (1%)	
Calcium, mmol/L	2.20-2.55	2.1(2.0-2.2)	2.0(1.9-2.2)	2.1(2.1-2.3)	0.00
					4
<2.2		70 (69%)	14 (93%)	56 (64%)	0.02
					6
≥2.2		32 (31%)	1 (7%)	31 (36%)	
Procalcitonin, ng/mL	< 0.05	0.06(0.03-	0.19(0.12-	0.05(0.03-	0.00
		0.15)	0.60)	0.10)	0
< 0.05		40 (39%)	0 (0%)	40 (46%)	0.00
					0
≥0.05		62 (61%)	15 (100%)	47 (54%)	
High-sensitivity C-reactive	<1	34.0(5.8-	78.7(51.3-	25.4(3.9-	0.00
Protein (hs-CRP), mg/L		86.6)	166.3)	81.3)	3
<3		16 (16%)	0 (0%)	16 (18%)	0.11
		,	,		9
≥3		86 (84%)	15 (100%)	71 (82%)	
IL-1β, pg/ml	<5	4.9(4.0-4.9)	` ,	4.9(4.0-4.9)	0.38
		,	,		8
IL-2R, U/ml	223-710	605.5(380.8	1166.5(898.8	571.5(353.	0.00
,		-896.8)	•	`	1
IL-6, pg/ml	<7	4.7(2.2-	48.4(12.6-	<i>'</i>	0.00
713		20.3)	154.1)	16.4)	0
IL-8, pg/ml	<62	10.2(6.7-	22.0(14.0-	9.3(6.4-	0.00
, 18	<u> </u>	19.9)	28.4)	18.6)	6
IL-10, pg/ml	<9.1	4.9(4.0-4.9)	4.9(4.0-10.0)	4.9(4.0-4.9)	0.60
· · · , r Ø		((20.0)	(1
TNF-α, pg/ml	<8.1	7.5(5.6-	13.0(8.3-	7.3(5.6-9.4)	0.00
	J.1	10.1)	23.3)	(2.0).1)	6
		10.1	2 3.3 j		J

Data are median (IQR), n (%), or n/N (%), where N is the total number of patients with available data. p values comparing survivor with non-survivor were calculated by χ^2 test, Fisher's exact test, or Mann-Whitney U test, as appropriated. Covid-19, coronavirus disease 2019.

Table S3. Risk factors associated with fatality

	Univariable	p value	Multivariable	p value
	OR (95% CI)		OR (95% CI)	
Demographics and clinical cl	naracteristics			
Age, years*	1.07(1.02-1.11)	0.006	1.063(1.006-1.124)	0.031
<65	1 (ref)			
≥65	4.17(1.34-13.02)	0.014		
Female sex (vs male)	0.45(0.13-1.52)	0.196		
Comorbidity present				
(vs not present)				
Diabetes	0.88(0.18-4.34)	0.871		
Hypertension	2.30(0.75-7.03)	0.120		
Coronary heart disease	6.54(0.85-50.54)	0.072		••
Other	1.39(0.43-4.50)	0.582		
Current smoker	0.96(0.11-8.63)	0.974		
Laboratory findings				
White blood cell count,	1.29(1.07-1.56)	0.008	••	
\times 10 9 /L	,			
<4	0.84(0.09-7.43)	0.873		
4–10	1 (ref)			
>10	5.03(1.44-17.54)	0.011		
Neutrophil count, × 10 ⁹ /L*	1.33(1.11-1.59)	0.002		
Lymphocyte count, × 10 ⁹ /L*	0.17(0.04-0.79)	0.024		
Platelet count, × 109/L	0.98(0.97-0.99)	0.001		
<125	16.93(4.66-61.51)	0.000		
≥125	1 (ref)			
Lactate dehydrogenase,	1.01(1.00-1.02)	0.000	1.010(1.005-1.015)	0.000
U/L*				
≤225	1 (ref)			
>225	5.97(0.75-47.77)	0.092		
D-dimer, µg/mL	1.14(1.04-1.25)	0.007		
≤0.5	1 (ref)			
>0·5 to ≤1	0.96(0.06-16.21)	0.980		
>1	10.97(1.35-89.34)	0.025		
Prothrombin time, s	1.08(0.96-1.21)	0.210		
<14.5	1 (ref)			
≥14.5	6.45(1.88-22.14)	0.003		
Hypersensitive troponin I,	1.00(0.99-1.01)	0.313		
pg/mL				
≤34.2	1 (ref)	••		
>34.2	11.67(3.15-43.26)	0.000		••

NT-proB-type natriuretic	1.00(1.00-1.00)	0.706	 ••
peptide (BNP), pg/mL			
<241	1 (ref)		
≥241	35.61(4.41-287.68)	0.001	
Albumin, g/L	0.82(0.71-0.93)	0.003	
<35	8.00(1.70-37.60)	0.008	
≥35	1 (ref)		
Alanine aminotransferase,	0.97(0.93-1.02)	0.204	
U/L			
≤41	1 (ref)		
>41	0.34(0.04-2.81)	0.319	
Creatinine, µmol/L	1.00(0.99-1.01)	0.535	
≤104	1 (ref)		
>104	7.62(2.10-27.68)	0.002	
Blood urea nitrogen, mmol/L	1.12(1.02-1.23)	0.018	
≤9.5	1 (ref)		
>9.5	18.16(4.36-75.62)	0.000	
Procalcitonin, ng/mL*	1.86(0.82-4.20)	0.138	
High-sensitivity C-reactive	1.01(1.00-1.02)	0.005	
Protein (hs-CRP), mg/L*			
IL-2R, U/ml*	1.003(1.001-1.004)	0.001	
IL-6, pg/ml*	1.02(1.01-1.04)	0.002	
TNF-α, pg/ml*	1.19(1.06-1.34)	0.005	

OR=odds ratio. *Per 1 unit increase.

Table S4. CT features of patients with Covid-19

	Week 1 (\leq 7d)	after symptom onset	Week 2 (> 7d, \leq 14d)	Week $3(>14d, \le 21d)$	Week $4(>21d, \le 28d)$
	Survivor (n=21)	Non-Survivor (n=11)	Survivor (n=22)	Survivor (n=25)	Survivor (n=23)
Severity score of each lobe					
Right upper lobe	1 (0-1.5)	3 (2-4) ***	2 (1-2)	1 (0.5-2)	1 (0-2)
Right middle lobe	0 (0-1)	2 (1-2)	1 (0-1)	0 (0-1)	0 (0-1)
Right lower lobe	1 (1-3)	3 (3-4)	2.5 (1-3)	1 (1-2.5)	1 (1-2)
Left upper lobe	1 (0-1.5)	3 (1-4)	1.5 (0-3)	1 (0-2)	1 (0-2)
Left lower lobe	1 (0-2.5)	4 (3-5) ***	2 (1-3.25)	1 (1-2.5)	1 (0-2)
Total severity score	4 (2-9.5)	15 (9-19) ****	8 (4-12.25) *	5 (3-10)	4 (2-9)
<15	20 (95.24%)	4 (36.36%) ***	19 (86.36%)	23 (92%)	22 (95.65%)
≥15	1 (4.76%)	7 (63.64%)	3 (13.64%)	2 (8%)	1 (4.35%)
Number of involved lobes	3 (1.5-5)	5 (4-5) **	4.5 (3-5)	4 (3-5)	3 (2-5)
<5	14 (66.67%)	2 (18.18%) *	11 (50%)	15 (60%)	14 (60.87%)
=5	7 (33.33%)	9 (81.82%)	11 (50%)	10 (40%)	9 (39.13%)
Lung involvement					
No involvement	2 (9.52%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Unilateral	4 (19.05%)	0 (0%)	0 (0%)	4 (16%)	3 (13.04%)
Bilateral	15 (71.43%)	11 (100%) *	22 (100%)	21 (84%)	20 (86.96%)
Patterns of opacification					
Ground glass opacity	20 (95.24%)	10 (90.91%)	21 (95.45%)	18 (72%) *	20 (86.96%)
Crazy-paving pattern	2 (9.52%)	5 (45.45%) **	5 (22.72%)	3 (12%)	4 (17.39%)
Consolidation	9 (42.86%)	9 (81.82%) *	15 (68.19%)	14 (56%)	1 (4.35%) **
Reticulation	0 (0%)	2 (18.18%) *	3 (13.64%)	9 (36%) **	15 (65.22%) ***
Pleural effusion	1 (4.76%)	3 (27.27%)	1 (4.55%)	0 (0%)	0 (0%)

Distribution of opacification					
No lesion	2 (9.52%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Peripheral	10 (47.62%)	8 (72.73%)	13 (59.09%)	18 (72%)	17 (73.91%)
Random	6 (28.57%)	0 (0%) *	2 (9.09%)	0 (0%) **	0 (0%) **
Diffuse	3 (14.29%)	3 (21.27%)	7 (31.82%)	7 (28%)	6 (26.09%)
Time between symptom onset and CT scan	4 (2.5-5)	5 (2-6)	11.5 (9-13.25)	18 (16-20)	26 (24-28)

Data are median (IQR), n (%). χ^2 test, Mann-Whitney U test and Fisher's exact test were used to compare the values of survivors in Week 1 with those of non-survivors, and with those of survivors in Week 2, 3, 4, respectively. ****, p < 0.0001; ***, p < 0.001; **, p < 0.01; *, p < 0.05.

Table S5. Risk factors associated with fatality of the subset of patients with CT severity scores within the first week after symptom onset

	Univariable	p	Multivariable	p
	OR (95% CI)	value	OR (95% CI)	value
Demographics				
Age, years*	1.06(1.01-1.13)	0.027		
Laboratory findings on adm	ission			
Lymphocyte count,	0.53(0.09-3.03)	0.474	••	
$\times 10^9/L*$				
Lactate dehydrogenase, U/L	1.01(1.00-1.02)	0.003	••	
≤225	1 (ref)			
>225	6.15(0.66-57.60)	0.111		
D-dimer, μg/mL	9.30(1.85-46.74)	0.007		
≤0.5	1 (ref)			
>0.5 to ≤ 1				
>1	23.33(1.99-273.29)	0.012		
Hypersensitive troponin I,	1.00(0.99-1.01)	0.411		
pg/mL				
≤34.2	1 (ref)			
>34.2	7.50(1.14-49.26)	0.036		
CT findings within the first v	week after symptom or	ıset		
Total severity score*	1.39(1.12-1.72)	0.003	1.544(1.004-2.374)	0.048
<15	1 (ref)		••	
≥15	35.00(3.32-368.57)	0.003	••	
Number of involved lung	1.366(1.003-1.860)	0.048		
lobes				
<5	1 (ref)		••	
=5	9.00(1.52-53.40)	0.016	••	

OR=odds ratio. *Per 1 unit increase.

Table S6. Demographics and baseline characteristics of the subset of patients included in the analysis of CT within the first week after symptom onset

	Total	Non-survivor	Survivor	p
	(n=32)	(n=11)	(n=21)	value
Characteristics				
Age, years	58(40-70)	69(57-78)	51(33-70)	0.020
<65	20 (62%)	5 (45%)	15 (71%)	0.149
≥65	12 (38%)	6 (55%)	6 (29%)	
Sex				0.266
Female	13 (41%)	3 (27%)	10 (48%)	
Male	19 (59%)	8 (73%)	11 (52%)	
Any Comorbidity	13 (41%)	6 (55%)	7 (33%)	0.246
Diabetes	5 (16%)	2 (18%)	3 (14%)	0.773
Hypertension	9 (28%)	5 (45%)	4 (19%)	0.115
Coronary heart disease	1 (3%)	1 (9%)	0 (0%)	0.344
Chronic obstructive	1 (3%)	1 (9%)	0 (0%)	0.344
pulmonary disease				
Malignancy	0 (0%)	0 (0%)	0 (0%)	
Chronic liver disease	1 (3%)	0 (0%)	1 (5%)	1.000
Other	8 (25%)	4 (36%)	4 (19%)	0.283
Current smoker	3 (9%)	1 (9%)	2 (10%)	0.968
Symptoms and signs				
Fever	30 (94%)	10 (91%)	20 (95%)	0.631
Highest temperature, °C	38.6(38.0-39.0)	38.6(37.6-39.0)	38.5(38.0-39.0)	0.611
Chills	7 (22%)	3 (27%)	4 (19%)	0.593
Cough	23 (72%)	9 (82%)	14 (67%)	0.365
Sputum	8 (25%)	5 (45%)	3 (14%)	0.053
Dyspnea	16 (50%)	5 (45%)	11 (52%)	0.710
Hemoptysis	2 (6%)	1 (9%)	1 (5%)	0.631
Chest pain	2 (6%)	1 (9%)	1 (5%)	0.631
Headache	3 (9%)	1 (9%)	2 (10%)	0.968
Fatigue	8 (25%)	2 (18%)	6 (29%)	0.519
Nausea	1 (3%)	0 (0%)	1 (5%)	1.000
Diarrhea	5 (16%)	3 (27%)	2 (10%)	0.189
Myalgia	7 (22%)	3 (27%)	4 (19%)	0.593
Systolic pressure, mm Hg	129.0(114.0-	144.0(125.0-	126.0(112.0-	0.074
	144.0)	171.0)	139.0)	
Heart rate, beats per minute	95.0(81.0-110.0)	103.0(86.0-	86.0(80.0-109.0)	0.367
		111.0)		
Respiratory rate	20.0(20.0-24.0)	24.0(20.0-25.0)	20.0(20.0-22.0)	0.022
>20 breaths per min	14 (44%)	8 (73%)	6 (29%)	0.017

Time from symptom onset	10.0(7.0-13.0)	8.0(6.0-14.0)	10.0(7.0-13.0)	0.639
to hospital admission, days				

Data are median (IQR), n (%), or n/N (%), where N is the total number of patients with available data. χ^2 test, Fisher's exact test, or Mann-Whitney U test were used to compare the values between survivors and non-survivors as appropriate.

Table S7. Laboratory findings of the subset of patients included in the analysis of CT within the first week after symptom onset

	Normal range	Total	Non-survivor	Survivor	p value
		(n=32)	(n=11)	(n=21)	
White blood cell count, × 109/L	4.00-10.00	5.2(4.2-8.3)	9.1(6.2-11.8)	4.7(4.1-5.4)	0.000
<4		4 (13%)	0 (0%)	4 (19%)	0.002
4–10		23 (72%)	6 (55%)	17 (91%)	
>10		5 (15%)	5 (45%)	0 (0%)	
Neutrophil count, × 10°/L	1.80-6.30	3.5(2.8-6.9)	8.0(3.5-11.3)	2.9(2.7-4.3)	0.000
Lymphocyte count, × 109/L	1.10-3.20	0.8(0.5-1.2)	0.7(0.4-1.5)	0.9(0.6-1.2)	0.307
<1·1		22 (69%)	8 (73%)	14 (67%)	0.725
≥1·1		10 (31%)	3 (27%)	7 (33%)	
Hemoglobin, g/L	130.0-175.0	126.5(120.0-140.0)	120.0(110.0-135.0)	129.0(122.5-141.5)	0.113
Platelet count, × 10°/L	125.0-350.0	162.0(124.0-242.0)	124.0(87.0-242.0)	175.0(133.8-287.0)	0.066
<125		8/31 (26%)	6 (55%)	2/20 (10%)	0.007
≥125		23/31 (74%)	5 (45%)	18/20 (90%)	
Lactate dehydrogenase, U/L	135-225	328.0(197.5-541.8)	570.0(440.0-671.0)	261.0(194.5-379.5)	0.001
≤225		9 (28%)	1 (9%)	8 (38%)	0.083
>225		23 (72%)	10 (91%)	13 (62%)	
D-dimer, µg/mL	≤0.5	0.9(0.5-2.0)	2.3(1.6-22.0)	0.6(0.4-0.9)	0.000
≤0.5		8 (25%)	1 (9%)	7 (33%)	0.000
>0·5 to ≤1		11 (34%)	0 (0%)	11 (52%)	
>1		13 (41%)	10 (91%)	3 (15%)	
Prothrombin time, s	11.5-14.5	14.8(13.8-15.4)	15.5(14.8-17.7)	14.3(13.4-15.0)	0.005
<14.5		14 (44%)	2 (18%)	12 (57%)	0.035

≥14.5		18 (56%)	9 (82%)	9 (43%)	
International Normalized Ratio, INR	0.80-1.20	1.15(1.05-1.20)	1.21(1.14-1.45)	1.09(1.01-1.17)	0.005
Hypersensitive troponin I, pg/mL	≤34.2	11.0(4.2-27.0)	23.1(13.0-204.7)	6.0(2.3-13.2)	0.005
≤34.2		24/31 (77%)	6 (55%)	18/20 (90%)	0.024
>34.2		7/31 (23%)	5 (45%)	2/20 (10%)	
NT-proB-type Natriuretic Peptide (BNP), pg/mL	<241	192.0(71.0-702.5)	777.0(348.5-2847.0)	90.5(58.8-194.5)	0.000
<241		17/30 (57%)	0 (0%)	17/20 (85%)	0.000
≥241		13/30 (43%)	10 (100%)	3/20 (15%)	
Albumin, g/L	35-52	33.4(30.1-39.5)	31.5(28.2-34.2)	36.0(32.2-39.9)	0.034
<35		18 (56%)	9 (82%)	9 (43%)	0.035
≥35		14 (44%)	2 (18%)	12 (57%)	
Alanine aminotransferase, U/L	≤41	19.5(13.0-28.5)	17.0(14.0-29.0)	20.0(12.0-27.5)	0.725
≤41		28 (87%)	10 (91%)	18 (86%)	0.673
>41		4 (13%)	1 (9%)	3 (14%)	
Aspartate aminotransferase, U/L	≤40	30.0(19.3-43.0)	34.0(24.0-54.0)	24.0(19.0-36.0)	0.271
≤40		24 (75%)	7 (64%)	17 (81%)	0.283
>40		8 (25%)	4 (36%)	4 (19%)	
Total bilirubin, μmol/L	≤26	7.9(6.2-10.3)	7.5(6.6-9.8)	8.1(6.0-10.9)	1.000
Creatinine, µmol/L	59-104	68.0(61.3-87.8)	100.0(62.0-164.0)	67.0(59.5-76.0)	0.088
≤104		27 (84%)	6 (55%)	21 (100%)	0.002
>104		5 (16%)	5 (45%)	0 (0%)	
Blood urea nitrogen, mmol/L	3.6-9.5	4.7(3.3-8.4)	9.2(5.4-13.7)	4.0(3.3-5.2)	0.008
≤9.5		26 (81%)	6 (55%)	20 (95%)	0.005
>9.5		6 (19%)	5 (45%)	1 (5%)	
Potassium, mmol/L	3.50-5.10	4.1(3.5-4.5)	4.4(3.6-5.3)	4.0(3.5-4.3)	0.208
<3.5		7 (22%)	2 (18%)	5 (24%)	0.042

3.5-5.1		22 (69%)	6 (55%)	16 (76%)	
>5.1		3 (9%)	3 (27%)	0 (0%)	
Sodium, mmol/L	136-145	139.0(136.4-141.9)	138.7(137.2-142.6)	139.1(135.6-141.7)	0.938
<136		7 (22%)	2 (18%)	5 (24%)	0.363
136-145		24 (75%)	8 (73%)	16 (76%)	
>145		1 (3%)	1 (9%)	0 (0%)	
Calcium, mmol/L	2.20-2.55	2.1(2.0-2.2)	2.0(1.9-2.2)	2.1(2.0-2.2)	0.081
<2.2		25 (78%)	10 (91%)	15 (71%)	0.205
≥2.2		7 (22%)	1 (9%)	6 (29%)	
Procalcitonin, ng/mL	< 0.05	0.05(0.03-0.18)	0.32(0.11-0.60)	0.04(0.02-0.06)	0.000
< 0.05		17 (53%)	1 (9%)	16 (76%)	0.000
≥0.05		15 (47%)	10 (91%)	5 (24%)	
High-sensitivity C-reactive Protein (hs-CRP), mg/L	<1	52.2(9.6-114.7)	102.1(51.3-194.8)	27.0(5.5-71.1)	0.009
<3		4 (13%)	0 (0%)	4 (19%)	0.272
≥3		28 (87%)	11 (100%)	17 (81%)	
IL-1β, pg/ml	<5	4.9(4.7-4.9)	4.9(4.2-4.9)	4.9(4.7-4.9)	0.652
IL-2R, U/ml	223-710	514.0(292.5-744.5)	1076.5(671.8-1699.5)	454.5(270.3-563.0)	0.005
IL-6, pg/ml	<7	4.5(1.4-22.6)	65.1(11.3-154.1)	3.3(1.4-16.7)	0.019
IL-8, pg/ml	<62	10.2(6.1-18.9)	27.6(14.1-64.9)	9.4(5.7-15.9)	0.010
IL-10, pg/ml	<9.1	4.9(4.0-4.9)	8.3(4.9-17.0)	4.9(4.0-4.9)	0.081
TNF-α, pg/ml	<8.1	7.0(4.9-9.6)	21.3(13.2-28.9)	5.7(3.8-7.9)	0.000

Data are median (IQR), n (%), or n/N (%), where N is the total number of patients with available data. χ^2 test, Fisher's exact test, or Mann-Whitney U test were used to compare the values between survivors and non-survivors as appropriate.




Figure S1. Transverse CT images of a 38-year-old man with Covid-19. A, Normal CT images on the day when the patient had initial symptoms (day 1). B, day 9 after symptom onset, bilateral and peripheral ground-grass opacity associated smooth interlobular and intralobular septal thickening (crazy-paving pattern). C, day 15 after symptom onset, peripheral predominant consolidation pattern with air bronchograms in right upper and lower lobes. D, day 23 after symptom onset, previous opacifications were dissipated into ground-grass opacities and irregular interlobular and intralobular septal thickening (reticulation pattern). E, day 30 after symptom onset, further resolution of the lesions, ground-glass opacities and reticulation patterns remained.




Figure S2. Transverse CT images of a 41-year-old woman with Covid-19. A-C, day 6 after symptom onset, multifocal consolidations and ground-glass opacities affecting the bilateral, subpleural lung parenchyma associated with crazy-paving pattern. D-F, day 10 after symptom onset, bilateral extensive ground-glass opacities, involving nearly the entire lower lobes and right middle lobe, and most of the upper lobes, giving a white lung appearance, with air bronchograms and crazy-paving pattern. The patient died 8 days after this scan.

Author Contributions

KL and GZ conceptualized the study design. KL, SC, DC, YF, CC collected

demographic, clinical, and laboratory data. ZW and NW interpreted the images of CT

scans. KL, DC, YF and GZ analysed the data. KL and GZ interpreted the results. GZ

wrote the manuscript with all authors providing feedback for revision. All authors read

and approved the final report.

Funding

Supported by National Natural Science Foundation of China (grants 81670019,

91742108), National Key Research and Development Program of China

(2016YFC1304400).

Acknowledgement

We are very grateful to all members of the medical, nursing, and support staffs of the

quarantine unit at the Sino-French branch of Tongji Hospital for their support. We are

very grateful to David J. Erle (University of California San Francisco) for the critical

review of the manuscript.

Declaration of interests

The authors have no competing interests to declare.

References

1. World Health Organization. Clinical management of severe acute respiratory

infection when novel coronavirus (2019-nCoV) infection is suspected: interim

guidance. January 28, 2020 (https://www.who.int/docs/default - source/coronaviruse/

clinical-management-of-novel-cov.pdf)

26 / 27

- 2. Chang Y, Yu C, Chang S, et al. Pulmonary sequelae in convalescent patients after severe acute respiratory syndrome: evaluation with thin-section CT. Radiology 2005;236(3):1067-1075
- 3. World Health Organization. Coronavirus disease (COVID-19) technical guidance: laboratory testing for 2019-nCoV in humans (https://www.who.int/emergencies/ diseases/ novel -coronavirus-2019/ technical-guidance/ laboratory-guidance)